Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy

Shu-Hui Lv,1– 3,* Wang-Zhong Li,1,2,* Hu Liang,1,2 Guo-Ying Liu,1,2 Wei-Xiong Xia,1,2 Yan-Qun Xiang1,2 1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lv SH, Li WZ, Liang H, Liu GY, Xia WX, Xiang YQ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	nasopharyngeal carcinoma inflammatory biomarkers circulating inflammation signature prognostic value predictive value induction chemotherapy Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/47845f181ea044c3930be72e0ef0cf59
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:47845f181ea044c3930be72e0ef0cf59
record_format	dspace
spelling	oai:doaj.org-article:47845f181ea044c3930be72e0ef0cf592021-12-02T14:57:42ZPrognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy1178-7031https://doaj.org/article/47845f181ea044c3930be72e0ef0cf592021-05-01T00:00:00Zhttps://www.dovepress.com/prognostic-and-predictive-value-of-circulating-inflammation-signature--peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Shu-Hui Lv,1– 3,* Wang-Zhong Li,1,2,* Hu Liang,1,2 Guo-Ying Liu,1,2 Wei-Xiong Xia,1,2 Yan-Qun Xiang1,2 1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, China; 2Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, China; 3Medical Affairs Office, The Fifth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yan-Qun Xiang; Wei-Xiong XiaDepartment of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, ChinaTel\Fax +86-1866-6096-623 Email xiangyq@sysucc.org.cn; xiawx@sysucc.org.cnPurpose: We sought to assess the prognostic and predictive value of a circulating inflammation signature (CISIG) and develop CISIG-based tools for predicting prognosis and guiding individualized induction chemotherapy (ICT) in non-metastatic nasopharyngeal carcinoma (NPC).Patients and Methods: We retrospectively collected a candidate inflammatory biomarker panel from patients with NPC treated with definitive radiotherapy between 2012 and 2017. We developed the CISIG using candidate biomarkers identified by a least absolute shrinkage and selection operator (LASSO) Cox regression model. The Cox regression analyses were used to evaluate the CISIG prognostic value. A CISIG-based prediction model was constructed, validated, and assessed. Potential stratified ICT treatment effects were examined.Results: A total of 1149 patients were analyzed. Nine biomarkers selected by LASSO regression in the training cohort were used to construct the CISIG, including hyaluronidase, laminin, procollagen III, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, high-density lipoprotein, lactate dehydrogenase, and C-reactive protein-to-albumin ratio. CISIG was an independent prognostic factor for disease-free survival (DFS; hazard ratio: 2.65, 95% confidence interval: 1.93– 3.64; P < 0.001). High CISIG group (>− 0.2) was associated with worse 3-year DFS than low CISIG group in both the training (67.5% vs 88.3%, P < 0.001) and validation cohorts (72.3% vs 85.1%, P < 0.001). We constructed and validated a CISIG-based nomogram, which showed better performance than the clinical stage and Epstein–Barr virus DNA classification methods. A significant interaction between CISIG and the ICT treatment effect was observed (P for interaction = 0.036). Patients with high CISIG values did not benefit from ICT, whereas patients with low CISIG values significantly benefited from ICT.Conclusion: The developed CISIG, based on a circulating inflammatory biomarker panel, adds prognostic information for patients with NPC. The proposed CISIG-based tools offer individualized risk estimation to facilitate suitable ICT candidate identification.Keywords: nasopharyngeal carcinoma, inflammatory biomarkers, circulating inflammation signature, prognostic value, predictive value, induction chemotherapyLv SHLi WZLiang HLiu GYXia WXXiang YQDove Medical Pressarticlenasopharyngeal carcinomainflammatory biomarkerscirculating inflammation signatureprognostic valuepredictive valueinduction chemotherapyPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 2225-2237 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	nasopharyngeal carcinoma inflammatory biomarkers circulating inflammation signature prognostic value predictive value induction chemotherapy Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	nasopharyngeal carcinoma inflammatory biomarkers circulating inflammation signature prognostic value predictive value induction chemotherapy Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Lv SH Li WZ Liang H Liu GY Xia WX Xiang YQ Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy
description	Shu-Hui Lv,1– 3,* Wang-Zhong Li,1,2,* Hu Liang,1,2 Guo-Ying Liu,1,2 Wei-Xiong Xia,1,2 Yan-Qun Xiang1,2 1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, China; 2Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, China; 3Medical Affairs Office, The Fifth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yan-Qun Xiang; Wei-Xiong XiaDepartment of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, ChinaTel\Fax +86-1866-6096-623 Email xiangyq@sysucc.org.cn; xiawx@sysucc.org.cnPurpose: We sought to assess the prognostic and predictive value of a circulating inflammation signature (CISIG) and develop CISIG-based tools for predicting prognosis and guiding individualized induction chemotherapy (ICT) in non-metastatic nasopharyngeal carcinoma (NPC).Patients and Methods: We retrospectively collected a candidate inflammatory biomarker panel from patients with NPC treated with definitive radiotherapy between 2012 and 2017. We developed the CISIG using candidate biomarkers identified by a least absolute shrinkage and selection operator (LASSO) Cox regression model. The Cox regression analyses were used to evaluate the CISIG prognostic value. A CISIG-based prediction model was constructed, validated, and assessed. Potential stratified ICT treatment effects were examined.Results: A total of 1149 patients were analyzed. Nine biomarkers selected by LASSO regression in the training cohort were used to construct the CISIG, including hyaluronidase, laminin, procollagen III, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, high-density lipoprotein, lactate dehydrogenase, and C-reactive protein-to-albumin ratio. CISIG was an independent prognostic factor for disease-free survival (DFS; hazard ratio: 2.65, 95% confidence interval: 1.93– 3.64; P < 0.001). High CISIG group (>− 0.2) was associated with worse 3-year DFS than low CISIG group in both the training (67.5% vs 88.3%, P < 0.001) and validation cohorts (72.3% vs 85.1%, P < 0.001). We constructed and validated a CISIG-based nomogram, which showed better performance than the clinical stage and Epstein–Barr virus DNA classification methods. A significant interaction between CISIG and the ICT treatment effect was observed (P for interaction = 0.036). Patients with high CISIG values did not benefit from ICT, whereas patients with low CISIG values significantly benefited from ICT.Conclusion: The developed CISIG, based on a circulating inflammatory biomarker panel, adds prognostic information for patients with NPC. The proposed CISIG-based tools offer individualized risk estimation to facilitate suitable ICT candidate identification.Keywords: nasopharyngeal carcinoma, inflammatory biomarkers, circulating inflammation signature, prognostic value, predictive value, induction chemotherapy
format	article
author	Lv SH Li WZ Liang H Liu GY Xia WX Xiang YQ
author_facet	Lv SH Li WZ Liang H Liu GY Xia WX Xiang YQ
author_sort	Lv SH
title	Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy
title_short	Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy
title_full	Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy
title_fullStr	Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy
title_full_unstemmed	Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy
title_sort	prognostic and predictive value of circulating inflammation signature in non-metastatic nasopharyngeal carcinoma: potential role for individualized induction chemotherapy
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/47845f181ea044c3930be72e0ef0cf59
work_keys_str_mv	AT lvsh prognosticandpredictivevalueofcirculatinginflammationsignatureinnonmetastaticnasopharyngealcarcinomapotentialroleforindividualizedinductionchemotherapy AT liwz prognosticandpredictivevalueofcirculatinginflammationsignatureinnonmetastaticnasopharyngealcarcinomapotentialroleforindividualizedinductionchemotherapy AT liangh prognosticandpredictivevalueofcirculatinginflammationsignatureinnonmetastaticnasopharyngealcarcinomapotentialroleforindividualizedinductionchemotherapy AT liugy prognosticandpredictivevalueofcirculatinginflammationsignatureinnonmetastaticnasopharyngealcarcinomapotentialroleforindividualizedinductionchemotherapy AT xiawx prognosticandpredictivevalueofcirculatinginflammationsignatureinnonmetastaticnasopharyngealcarcinomapotentialroleforindividualizedinductionchemotherapy AT xiangyq prognosticandpredictivevalueofcirculatinginflammationsignatureinnonmetastaticnasopharyngealcarcinomapotentialroleforindividualizedinductionchemotherapy
_version_	1718389322559782912

Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy

Ejemplares similares